Rainbow Children's Medicare achieved its highest-ever annual revenue of ₹1,703.1 crore and PAT of ₹281.5 crore in FY26. The company added 440 beds and plans to add over 2,500 more in the next five years.
Rainbow Children's Medicare Reports Record Financials and Expansion Plans
Annual Revenue: ₹1,703.1 crore (12.4% YoY)
PAT: ₹281.5 crore (15.3% YoY)
Reader Takeaway: Record revenue and PAT driven by capacity expansion, balanced by talent and tech investment needs.
What just happened
Rainbow Children's Medicare Limited reported its highest-ever annual revenue of ₹1,703.1 crore, a 12.4% increase year-on-year. Profit After Tax (PAT) also reached a record high of ₹281.5 crore, up 15.3% YoY. EBITDA stood at ₹544.2 crore, growing 11.1% YoY. The company added 440 beds during the fiscal year and recommended a final dividend of ₹3.5 per share.
Why this matters
These results demonstrate strong operational performance and successful capacity expansion, indicating the company's ability to capitalize on the growing demand for specialized pediatric and maternity care. The record revenue and PAT signal financial health and effective growth strategies.
The backstory
This performance builds on a foundation of consistent growth from mature hospitals and effective implementation of the company's hub-and-spoke model. Capital expenditure in FY2026 was ₹217 crore, focused on expanding infrastructure.
What changes now
The company has a clear 5-year roadmap to add over 2,500 beds, nearly doubling its current network capacity to approximately 5,000 beds, with a planned investment of ₹2,200 crore. This aggressive expansion aims to solidify its market leadership.
Risks to watch
Key risks include headwinds in international patient inflows due to geopolitical and visa issues, intense competition for specialized medical talent, and ongoing high capital requirements for technology integration.
Peer comparison
(No direct peer comparison data provided in the filing).
Context metrics (time-bound)
- FY2026 Revenue: ₹1,703.1 crore (vs. ₹1,515.9 crore in FY2025)
- FY2026 EBITDA: ₹544.2 crore (vs. ₹489.9 crore in FY2025)
- FY2026 PAT: ₹281.5 crore (vs. ₹244.2 crore in FY2025)
- Beds Added in FY2026: 440
- Capital Expenditure in FY2026: ₹217 crore
- Planned 5-Year Bed Addition: Over 2,500 beds
- Planned 5-Year Investment: ₹2,200 crore
What to track next
Investors should monitor the occupancy rates of newly commissioned and acquired facilities, the successful execution of the 5-year bed capacity growth target, and the company's ability to mitigate risks related to international business and talent acquisition.